APLS Oct 2024 30.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:41AM EDT. Market open.
| Previous close | 0.8000 |
| Open | 1.5000 |
| Bid | 1.1500 |
| Ask | 1.9500 |
| Strike | 30.00 |
| Expiry date | 2024-10-18 |
| Day's range | 1.5000 - 1.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
ZacksApellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.
ZacksApellis Pharmaceuticals (APLS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Apellis Pharmaceuticals (APLS) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ZacksApellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of 0% and 7.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
© 2024 Yahoo. All rights reserved.